Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apollo Endosurgery, Inc.APEN · Entity 114713 | Director · 10% owner | December 29, 2016 | December 30, 2016 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | June 28, 2017 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apollo Endosurgery, Inc.
Report date December 29, 2016 · Filed December 30, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Remeditex Ventures, LLC | 1,309,392 |
Reported balance
After 2016-12-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-12-29 · Other · Acquired 1,309,392 · Balance 1,309,392 F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2: These securities are held in the name of Remeditex Ventures, LLC. The Reporting Person is Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding.
F2: These securities are held in the name of Remeditex Ventures, LLC. The Reporting Person is Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC.
Viridian Therapeutics, Inc.\DE
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.06 · Expires 2027-06-27 | Direct | 12,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 12,000 · Balance 12,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2017 Filed Jun 30, 2017 17:22 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-17-042572 · doc4.xml · derivative · entry 1 Creecy John W · CIK 0001689143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 08:33 UTC | Apollo Endosurgery, Inc. APEN · Entity 114713 | OtherCommon Stock | 1,309,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-033604 · edgar.xml · nonDerivative · entry 1 Creecy John W · CIK 0001689143 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Remeditex Ventures, LLC Disclosed balance after: 1,309,392 F1 · kind: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F1 · price: Shares of common stock of the corporation then known as Apollo Endosurgery, Inc. ("Old Apollo") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of September 8, 2016, by and among the Issuer, Merger Sub, Inc. and Old Apollo (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.3163 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every five and one half shares of common stock outstanding. F2 · ownership.nature: These securities are held in the name of Remeditex Ventures, LLC. The Reporting Person is Chief Executive Officer and Director of Remeditex Ventures, LLC and may be deemed to be the beneficial owner of the securities held by Remeditex Ventures, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.